Portal de Periódicos da CAPES

Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma

2006; Elsevier BV; Volume: 107; Issue: 8 Linguagem: Inglês

10.1182/blood-2005-11-4449

1528-0020

Niels W.C.J. van de Donk, Nicolaus Kröger, Ute Hegenbart, Paolo Corradini, Jesús F. San Miguel, Hartmut Goldschmidt, José Antonio Pérez‐Simón, Mark Zijlmans, Reinier Raymakers, Vittorio Montefusco, Francis Ayuk, Marinus H. J. van Oers, Arnon Nagler, Leo F. Verdonck, Henk M. Lokhorst,

Protein Degradation and Inhibitors

Nonmyeloablative conditioning can establish durable and stable engraftment with acceptable transplantation-related mortality (TRM) and excellent disease control in various hematologic malignancies, including multiple myeloma.[1][1],[2][2] We evaluated donor lymphocyte infusions (DLIs) given in 8